Baudax Bio, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The Company’s lead product candidate is IV injectable form of Meloxicam, a long-acting preferential cyclooxygenase (COX)-2 inhibitor. The Company’s product pipeline also includes other early-stage product candidates, including two neuromuscular blocker agents (NMBAs) and a related chemical reversal agent, and Dexmedetomidine (Dex)- intranasal (IN), an intranasal formulation of dexmedetomidine. The Company is developing an intermediate-acting NMBA, RP100; an ultrashort-acting NMBA, RP2000, and a reversal agent specific to its NMBAs.
Market Cap:67.7M; Shares Outstanding:9.4M; Q3 2019(9/30/19): Cash 0. Loss 10.31M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 106，no change
Shares hold: 5440.2k shares. no change
shares% hold: 58.18%，no change